A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms HIMALAYA
- Sponsors AstraZeneca
- 28 Nov 2018 Planned End Date changed from 26 Mar 2021 to 29 Jan 2021.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 26 Mar 2018 Planned End Date changed from 29 Mar 2021 to 26 Mar 2021.